Could my breast pain be caused by valsartan (angiotensin II receptor blocker) or carvedilol (non‑selective β‑blocker with α‑blocking activity)?

Breast Pain and Valsartan or Carvedilol

Neither valsartan nor carvedilol are established causes of breast pain, though medication-induced noncyclical mastalgia is poorly understood and can have various presentations 1.

Evidence for Drug-Induced Breast Pain

The ACR Appropriateness Criteria for breast pain explicitly acknowledge that "noncyclical breast pain due to various medications is poorly understood and has various presentations" 1. While the guidelines identify several medication classes that commonly cause breast pain—including:

• Hormonal medications (hormone replacement therapy, oral contraceptives, infertility treatments)
• Selective serotonin reuptake inhibitor (SSRI) antidepressants 1

Neither angiotensin II receptor blockers (ARBs) like valsartan nor beta-blockers like carvedilol are mentioned as common causes of breast pain in these comprehensive 2017 guidelines 1.

Specific Evidence on These Medications

Valsartan

The FDA label for valsartan does not list breast pain as a known adverse effect 2. Available research on valsartan focuses on:

• Cutaneous reactions (exanthematous drug eruption) 3
• Cardiovascular and renal effects 4
• Cancer risk (no increased risk found) 5

No published evidence links valsartan to breast pain.

Carvedilol

The FDA label for carvedilol does not list breast pain or gynecomastia as adverse effects 6. The label describes carvedilol as a "nonselective β-adrenergic blocking agent with α1-blocking activity" 6. While the drug has multiple pharmacologic actions, breast pain is not documented.

Importantly, there is one case report of atenolol (a different beta-blocker) causing breast pain and swelling 7. However, this represents:

• A single case with a different beta-blocker
• The authors noted "no reports of breast pain caused by this drug class were identified in the literature" 7
• Carvedilol has different pharmacologic properties than atenolol (carvedilol has α1-blocking activity; atenolol does not)

Clinical Approach

If your patient is experiencing breast pain while taking these medications:

1. Consider other causes first, as breast pain is extremely common (70-80% of women experience it at some time) 1:

   • Cyclical mastalgia (hormonal, most common—70% of cases) 1
   • Musculoskeletal/chest wall pain (costochondritis, muscle strain) 1
   • Other medications (SSRIs, hormonal therapies) 1
   • Breast pathology (though cancer rarely presents with pain alone) 1

2. Evaluate the temporal relationship: Did breast pain begin shortly after starting the medication? The atenolol case showed symptoms within 5 weeks 7.

3. Consider a trial discontinuation if:

   • Temporal relationship is strong
   • Other causes have been excluded
   • Alternative antihypertensive therapy is appropriate
   • The benefit-risk ratio favors switching (particularly important given these medications' proven mortality benefits in heart failure) 8, 9, 10, 11

4. Do not routinely discontinue these medications for breast pain without proper evaluation, as both drugs have proven cardiovascular benefits:

   • Carvedilol reduces mortality in heart failure by 35-65% 11
   • Valsartan is non-inferior to ACE inhibitors for cardiovascular outcomes 10

Key Caveat

The absence of evidence is not evidence of absence. While these medications are not documented causes of breast pain, medication-induced noncyclical mastalgia remains "poorly understood" 1. If a strong temporal relationship exists and other causes are excluded, consider switching to an alternative agent from a different class, particularly if the cardiovascular indication allows flexibility in drug selection.